San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, AltheaDx is raising $6,212,720.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Nikodem played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AltheaDx

We are a commercial stage molecular diagnostics company specializing in the field of pharmacogenetics, or PGx. IDgenetix, our PGx product testing portfolio, enables personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. Our bioinformatics platform and PGx product testing portfolio are intended to serve as a tool to assist healthcare providers in identifying optimal drugs for their patients as well as dosing guidelines based on a patient’s genetic make-up, current prescription regimen and other key factors. IDgenetix is designed to enable healthcare providers to make timely and evidence-based decisions, which we believe can reduce the overall cost of patient care by reducing adverse events, optimizing patients’ overall therapeutic regimen and helping to achieve a faster therapeutic response.

To learn more about AltheaDx, visit http://www.altheadx.com/

Contact:
David Nikodem, Chief Executive Officer
855-697-4943
https://www.linkedin.com/in/david-nikodem-ph-d-79825347/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved